Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy

We read with interest the study by Cordero et al. presenting their results1 of an intention-to-treat meta-analysis of the 4 CLEAR trials. Their study aims to consolidate the results of the CLEAR Outcomes trial. In that trial, bempedoic acid (BPA) proved to reduce a four-component major adverse cardiovascular event (MACE) endpoint, that included cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization, as well as fatal and non-fatal MI and coronary revascularization.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research